FACEBOOK  |  TWITTER  |  INSTAGRAM  |  LINKEDIN  |  Contact Us  |  Site Map
Get Involved

Eli Gilboa, PhD

Eli Gilboa, PhD
University of Miami Medical School
*Professor of Immunology & Microbiology*

What is your current professional status?

Professor of Immunology & Microbiology

What is your work setting (i.e. academic institution, government organization (i.e. FDA, NIH, etc.), bio-industry/pharmaceutical company, etc.)

Academic Institution

What is your scientific area of research?

Cancer Immunotherapy using oligonucleotide aptamer-targeted immune modulatory drugs.

Why do you want to be a mentor?

To advise junior investigators in the challenges and opportunities of a biomedical research career, and discuss the potential of cell-targeted RNA therapeutics in Medicine.

As a mentor, what are you hoping to gain from this experience?

To foster innovative, high-impact, albeit high-risk, research, specifically in the field of cell-targeted RNA therapeutics.    

How important are the following in the selection of a mentee: (1 – 5 scale, 1 = most important, 5 = least important)

            a. Compatibility of Scientific Specialties - 3
            b. Geographic Location - 5
            c. Professional Status / Success - 3 
            d. Compatibility of Career Path - 1
            e. Communication Style - 3

Summarized in a brief paragraph (150 words or less), please provide a biography that describes who you are and what you do in the field of gene and/or cell therapy.

I received my PhD from the Weizmann Institute in Israel and postdoctoral training at MIT, Boston. I am currently at the University of Miami Medical School. My lab is using oligonucleotide aptamers to modulate tumor immunity with the goal of reduced toxicity by in vivo targeting using aptamers as targeting ligands. We have introduced new concepts in cancer immunotherapy such as inducing neoantigens in disseminated tumor lesions, promoting immune memory, or targeting immune modulation to the tumor lesion. My lab has also made contributions to aptamer development using next generation sequencing, and demonstrated their exceptional efficiency to target siRNAs and aptamers to circulating immune cells and tumor lesions, respectively. New programs exploiting the unique features of the aptamer platform focus on reversing immune dysfunction in cancer and HIV infection, "coating" tumor cells and HIV virus with endogenous antibodies, and developing next generation aptamer-targeted RNA therapeutics.

Click here to view Eli Gilboa's CV.